肺表面活性物质防治早产儿肺透明膜病的临床回顾性分析  

Retrospective Analysis of Pulmonary Surfactant in the Prevention and Treatment of Hyaline Membrane Disease in Premature Infants

作　　者：方平[1] 陈玉蓉[1] 黄丽秀[1] 

机构地区：[1]川北医学院附属医院儿科,四川南充637000

出　　处：《川北医学院学报》2010年第6期519-521,共3页Journal of North Sichuan Medical College

摘　　要：目的:探讨肺表面活性物质(PS)防治早产儿肺透明膜病(HMD)的临床疗效。方法:155例出生体重<1500g或胎龄<34周的早产儿根据应用PS与否分为PS组(72例)和对照组(83例),比较两组早产儿HMD发病、并发症发生及转归情况、呼吸机使用、吸氧时间、体重增长及住院时间有无差异。结果:PS组的HMD及并发症发生率均低于对照组,呼吸机使用、吸氧时间及住院时间短于对照组,而体重增长优于对照组。结论:应用PS可降低早产儿HMD发生并改善早产儿预后。Objective： To evaluate the clinical efficacy of pulmonary surfactant（PS） in the prevention and treatment of hyaline membrane disease in premature infants.Methods： 155 premature infants with birth weight less than 1500g or gestational age less than 34 weeks were divided into a PS group（72 cases） and a control group（83 cases）.The incidence of hyaline membrane disease（HMD）,complications,prognosis,the time of the application of ventilator and usage of oxygen,the period in hospital stay and the weight gain were compared.Results： The incidence of HMD and complications of premature infants in the PS group were less than those in the control group,and the time of the application of ventilator and oxygen,the period in hospital stay in premature infants of PS group were shorter than those in the control group,while the weight gain of premature infants in the PS group was more than that in the control group.Conclusion： The application of PS in preterm infants reduced the occurrence of HMD and improved the prognosis.

关 键 词：肺表面活性物质 早产儿 肺透明膜病 

分 类 号：R722.1[医药卫生—儿科]